The first and only FDA-authorized treatment for opioid exposed newborns with neonatal opioid withdrawal syndrome (NOWS). Prapela is a breakthrough noninvasive stimulation therapy that naturally improves breathing and oxygenation in newborns. Based on a field of science called Stochastic Resonance, our precise and gentle stimulation improves breathing rhythm and lung function in newborns. Since 2017, we've received over $8M in awards and grants funding the clinical evaluation of our therapy to improve the treatment of opioid-exposed newborns and preterm infants with apnea of prematurity. For more information, visit prapela.com medical device, Pediatrics, neonatology, neonatal intensive care, therapy, apnea of prematurity, …

66 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Improving life for cancer patients through transformative drugs Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share …

65 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

LYMPHOGENiX is a leading company for lymphatic vessel regeneration research based in the UK and Japan operating globally LYMPHOGENiX is a UK-based biotechnology company focused on developing first-in-class therapeutics for infertility, leveraging a novel and underexplored biological system: the lymphatic vasculature. Infertility remains a major and growing global health challenge, affecting millions of individuals and couples worldwide. Despite advances in assisted reproductive technologies, implantation failure and poor endometrial receptivity continue to limit success rates. LYMPHOGENiX was founded to address this unmet need by targeting a fundamental but overlooked component of reproductive biology. Our core scientific insight is that lymphatic vessels …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The new painless treatment for Varicose Veins Developing a new approach to tumescent anesthesia delivery for endothermal varicose vein treatment. For investigational use only. The Solutio catheter has not been evaluated by the FDA and is not available for sale in the USA.

123 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Very close to you, us and your dream. FecunMed is a health center dedicated to the diagnosis and comprehensive treatment of sterility and infertility. We offer highly specialized treatments exclusively, since our sole purpose is the study, diagnosis and treatment of sterility and infertility. Assisted Reproduction

59 similar entities Type: SMB Activities: healthtech

a new wave of comfort and health. Wave Therapeutics, a Techstars company, has developed disruptive smart cushioning technology designed to prevent bedsores, save lives, and reduce a huge cost center for long-term and acute care facilities. Our devices help reduce the risks of bedsores and blood clots through a unique combination of tested medical therapies combined with powerful analytics capabilities. Using our technology healthcare facilities can reduce hospitalization stays and treatment costs, increase reimbursements, and eliminate crippling legal liabilities. Our technology is affordable, works better than anything else on the market, and has medical, consumer, and even military application with …

317 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Skin contamination is one of the most probable risks in Nuclear Accidental Exposure with release of radioactivity. In this case whether it is major nuclear or radiological incident in Nuclear Power Plant, a Military submarine base, a Nuclear medicine department or a Dirty Bomb, general public, first responders, workers and soldiers will be exposed and contaminated. The possibility of accidents made the development of new decontamination strategies crucial. Cevidra, Pharmaceutical Laboratory, in collaboration with Institute for Radiological Protection and Nuclear Safety (IRSN-French national public expert in nuclear and radiological risks) is developing, producing and commercializing worldwide the Calixarene Cevidra®, a …

44 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Innovative technology, safer outcomes. IDMED, a French company based in Marseille, develops and markets innovative medical devices in the fields of anesthesia and intensive care. Our products are used worldwide in operating theaters, intensive care units, neuro-ophthalmological consultations and research laboratories. Follow us on Facebook as well https://www.facebook.com/profile.php?id=100087269760737 Our products are commonly used in the areas of pupillometry, neuromuscular blockade monitoring and analgesia monitoring. IDMED develops products in collaboration with healthcare professionals. Innovation, reliability and relevance are the core qualities of our devices. We put our technical knowledge to the service of an improved everyday clinical practice. Healthcare, Medical device, …

373 similar entities Type: Startup Activities: deeptech manufacturing healthtech Technologies: Synthetic Biology

We CARE. We CREATE. We DELIVER. At LTS, our purpose drives everything we do: We CARE for patients, our partners , employees and communities, we CREATE innovative drug delivery solutions, and we DELIVER high-quality products to global markets with an exceptional track record in commercial manufacturing. As a global CDMO, we offer end-to-end development and manufacturing services for pharmaceutical and biotech companies. Our technology portfolio spans transdermal patches, oral thin films, nasal and sterile (drug delivery systems) dosage forms , wearable drug delivery devices as well as microneedle array patches. With over 40 commercial products and 50+ active development programs, …

131 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

You have the motivation, we have the rest! We are developing a new form of administration of active ingredients by vaporization. We operate in respiratory health around smoking cessation mainly and related diseases such as COPD/Asthma as well as pain management. Our development focuses on a vaporization medical device coupled with liquid medicinal formulations. Biotechnology, CBD, Health, Pharmaceuticals, vaporization, SEDEM, respiratory health, smoking cessation, COPD, and pain management

106 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Personalised fertility treatments, delivered with care | Clinical care, at-home convenience The future of fertility care is here. Affordable, at-home ICI-based fertility treatment designed to help you get you pregnant. Fertility and Medical Device

65 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Redefining Early Stage Development BDD combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through …

141 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Sensor technology for safer intravenous (IV) drug delivery to vulnerable patients Sencilia is an early-stage DeepTech/MedTech startup (spin off from the University of Groningen) with a mission to improve the safety and reliability of IV infusion therapy. We develop innovative sensor technology that is designed to enhance patient safety in neonatal, pediatric and adult intensive care by reducing the risk of IV infusion-related adverse drug events. Contact us to know more! (Disclaimer: This device is under development. It is an investigational device and is not available for commercial sale or clinical use in any jurisdiction. It has not been CE …

271 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the lives of patients. Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Boosting In Vitro Fertilisation Success Infertility is a global health problem, with a rising incidence, affecting one in every six couples and 190 million people worldwide. In Vitro Fertilisation (IVF), one of the most known infertility treatments, has gained awareness and clients. However, of the nearly a million IVF cycles done in Europe annually, only 40% result in pregnancy. Low IVF success makes the process long, expensive, and emotionally devastating. Manina Medtech is a young startup with a B2B business model and the vision that every woman who goes through IVF requires a single IVF cycle to get pregnant. We …

61 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Enhancing embryo implantation. Improving women’s fertility Oxolife is a biotechnology company dedicated to enhancing female fertility, with a focus on embryo implantation in women undergoing assisted reproductive technologies (ART). We are developing OXO-001, a first-in-class, non-hormonal oral treatment that directly targets the endometrium, enhancing embryo implantation and increasing Live Birth Rates (LBR). This innovative approach addresses an unmet medical need, as no drug currently exists to specifically increase embryo implantation rates, accounting for 65% Embryo Transfer failures. OXO-001 stands out due to its unique mechanism of action, offering a groundbreaking solution in the fertility space. Following the completion of our …

61 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Novel treatment paradigm for infertile women. Through targeting of the early and hormone-independent phase of egg maturation, we aim at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy.

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry. The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the …

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Stop hemorrhage instantly. Immediate & efficient postpartum hemorrhage control. Device based on physiological action. MATRIA Health Technologies develops cutting-edge medical devices designed to control and stop postpartum hemorrhage, the leading cause of maternal deaths worldwide. Our innovations ensure patient safety without any biological or chemical side effects. Medical Device, Surgery, Emergency, Obstetrics, Postpartum Hemorrhage, PPH, Start-Up, Innovation, Chirurgie obstétrique, Gynécologie, Gynecology, Healthcare, and Dispositifs médicaux

95 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

TRB Chemedica France is the subsidiary of the Swiss biotechnology group TRB Chemeda International. Founded in 1980, the TRB group specializes in the development, production and marketing of pharmaceutical products and medical devices in ophthalmology, rheumatology, orthopedics, sports medicine and neurology. The group is present around the world in more than 70 countries and is based on the strong values ​​of a family group on a human scale. For more than 20 years in France, TRB has been developing and marketing effective, safe and high-quality products based on sodium hyaluronate or hyaluronic acid to improve the quality of life of …

53 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

We created Rondol Industrie in 2012 with the goal of adapting Hot Melt Extrusion (HME) technology to the micro scale and to pharma standards and contributing therefore to better and cheaper healthcare. We are now HQ'd in Nancy, France. Rondol is a privately owned Deeptech company which patented the All-in-One Vertical twin screw extruder, representing a significant innovation in pharmaceutical manufacturing due to its capacity to increase the efficiency of drug formulation and delivery, and allowing for more effective therapeutic solutions. What sets this technology apart is its ability to handle complex formulations, enhance drug solubility, and improve bioavailability. These …

164 similar entities Type: Startup Activities: it services manufacturing Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Life-changing therapies for rare disease and oncology patients. Merger between EnBiotix Inc. and Polyphor AG. Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are urgently needed. Spexis AG was launched in December 2021 by the reverse merger of EnBiotix, Inc. (Boston, MA, USA) and Polyphor AG (Allschwil, Switzerland), with EnBiotix shareholders resulting in the majority. Our focus is on chronic respiratory diseases (CRD), and our lead product candidate ColiFin® is P3 ready. ColiFin® is an inhaled colistimethate sodium product in-licensed from PARI Pharma GmbH for ex-European …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Excellence in reproductive health The Vitrolife Group is a world-leading global provider of medical devices and genetic testing testing solutions. Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. Together we are now the Vitrolife Group, a global leader in reproductive health focused on supporting our customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced …

83 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

A clinical-stage company committed to addressing critical gaps in male and female fertility as well as women’s health ReproNovo was founded in 2021 by an experienced executive team with a strong track record in fertility and women’s health. The ReproNovo team brings strong expertise in drug development, regulatory affairs and business development, alongside a deep understanding of patient needs and the treatment landscape. Our team has successfully brought numerous therapies to market. Drawing upon our in-depth experience in designing and executing clinical programs, we are strongly committed to delivering innovative therapeutic solutions for male and female fertility and pioneering treatment …

102 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. Amplio Pharma is a privately owned wholly women founded pharmaceutical company. Our vision is to develop and apply modern-day technology to fix the short-comings from drugs that otherwise have a proven track record in their disease area. Our first development candidate, NovoBioJect (AMP101), is being developed to boost the responder rate to current 1st line RA treatment from ca 35% to up to 70%. We intend to reach …

120 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

NEW FRONTIERS IN NEUROSCIENCE Neurentis PLC is a late-clinical stage UK specialty pharma company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases. Our product pipeline is balanced with an advanced lead drug for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development as well as earlier stage drug candidates in collaboration with research institutions and other companies. The company is run by experienced ex-pharma industry executives, with more than 35 years’ experience in the sector each. The company’s low-risk commercial strategy is to commercialize …

382 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action …

231 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Created in 1986, POLIDIS Laboratory is a human-sized company which has built its reputation in the field of medical devices. Its recognized expertise in the world of condoms also extends to pregnancy tests, ovulation tests, pain relief gels, food supplements as well as a wide range of anti-lice and nit products (shampoo, treatment cream, two-phase lotion and nit remover). Its status as a French manufacturer as well as the excellent reputation of its products make Laboratoire POLIDIS a privileged partner of the French Pharmacy. Innovation is the key to success. This is why we ask our teams for the same …

187 similar entities Type: SMB Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

www.xspraypharma.com Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients’ quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval …

76 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Your strategic one-stop-shop partner. Your device, our care. Selenium Medical is a CDMO fully dedicated to medical devices and pharmaceutical applications. Behind every project lies a shared ambition: improving patients’ quality of life and well-being around the world. Certified to ISO 13485 and registered with the FDA and ANVISA, we support medical device manufacturers and healthcare professionals across the entire value chain, from co-development to market launch, through an integrated and tailored service offering. Our multidisciplinary teams combine technical expertise, regulatory know-how and a strong commitment to quality to deliver solutions tailored to the most complex projects, while ensuring reliability, …

445 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

225 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making the promise of gene therapy a reality Nanogenics is a UK research based virtual biotechnology company. Founded to develop the LipTideTM nanoformulation platform, the focus now is on developing product ECP105 through preclinical and towards clinical testing. ECP105 is under development for the treatment of Glaucoma patients undergoing trabeculectomy surgery. This surgical technique relieves intra-ocular pressure by creating a channel into which the eye drains. Although well established and successful, surgical failure can occur if the surgical wound undergoes fibrosis and the scar prevents drainage. The active ingredient of ECP105 is an siRNA designed to down-regulate a gene involved …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition …

577 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

MedActiv is a global leader in the development of transport and storage solutions for sensitive medication. Our products are designed to give users the freedom to travel knowing that their medication is kept at exactly the right temperature. As the chosen partner of major pharmaceutical companies worldwide, MedActiv is constantly pushing back the boundaries of this industry. The MedActiv solutions are specially designed to bring added value to the medications they are made for. Strategically located in France, UK, USA, Australia and Taiwan, we have the reputation of always anticipating the needs of our customers with an approach that is …

59 similar entities Type: Startup Activities: healthtech transporttech biotech

Medsteer, with offices in Paris/France (HQ) and New York/USA, is a leading technology provider in the field of closed loop systems for the delivery of anaesthesia drugs. The company’s patented technologies focus on drug delivery solutions guided by the cortical activity of the patient. Medsteer’s proprietary closed loop anesthesia technology (“EasyTIVA”) has been successfully tested in 25 multicenter clinical trials, representing 11 000 patient inclusions, 150 anesthesiologists and 50 operating rooms in Europe since 2003. Providing full automation and customization to the individual patient’s needs, closed loop anaesthesia opens up the way to a wide array of patient benefits associated …

92 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Translating genetic discoveries into safe and effective treatments. Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments. Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with …

368 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

234 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Reviving critical medicines Since 2013, Delbert Pharma has been preserving the market availability of drugs considered critical to our healthcare system and repositioning some for new indications, notably in rare diseases. Our commitment, as defenders of the pharmaceutical heritage, is to maintain access to essential medications to ensure the continuity of treatments for all. To support their European development, Laboratoires DELBERT become DELBERT Pharma in March 2024. This page is not intended to report adverse events that may be related to the medications marketed by Delbert Pharma. For this, please contact your healthcare professional. Delbert Pharma constantly monitors the safety …

77 similar entities Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

283 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Zero compromise contraception. We combine human-centred design & mucus engineering to launch a new era in contraception. Cirqle Biomedical combine human-centred design and mucus engineering to launch a new era in contraception.

58 similar entities Type: Startup Activities: deeptech healthtech

Controlled drug delivery for superior treatment. For patients, worldwide. Controlled drug delivery for superior treatment. For patients, worldwide. AMW’s mission as a specialty pharmaceutical company is to provide patients and our partners with value-added medicines for improved adherence and cost-effective therapies. With our focus on biodegradable controlled-release drug delivery systems suited for almost any indication, we build on our growing development pipeline. Based on our unparalleled expertise in formulation development, we collaborate with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions. We cover the entire value chain, from (co-)development to manufacturing and international commercialization …

83 similar entities Type: Startup Activities: deeptech biotech manufacturing healthtech Technologies: Synthetic Biology

Tailor-designed drug implants ​for local treatments. Founded by Truffle Capital. PK MED is a pioneering French biotechnology company founded in 2019 in Lyon, France, and supported by Truffle Capital, a leading European venture capital firm specializing in life sciences. We develop innovative biodegradable injectable micro-implants and advanced drug delivery technologies designed to address critical healthcare challenges. Our expertise spans rheumatology and novel cell homing approaches aimed at improving the success of bone marrow transplantation. Built on a team of experienced and passionate experts in pharmaceutical sciences, drug delivery, and biomaterials engineering, PK MED combines scientific excellence with innovation to develop …

98 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Delivery of vision care EyeD Pharma is a clinical stage pharmaceutical company dedicated to improving the life of patients suffering from ophthalmic diseases with unmet medical needs such as glaucoma or dry eye. We develop innovative therapeutic solutions based on sustained release polymeric micro-implants and inserts.

127 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

We want to improve the way people age Topadur Pharma AG is a Swiss biopharmaceutical scale-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. Topadur’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions. Topadur has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

616 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing antibiotic free treatment for vaginal infections Modern, antibiotic free treatment of vaginal infections Founded in 2015 in Lund, Sweden, Gedea Biotech is dedicated to developing safe and effective, antibiotic-free treatments for vaginal infections. Our lead product pHyph is an antibiotic free treatment for bacterial vaginosis that strengthens the healthy vaginal microbiome, supporting good vaginal health also in the long term. pHyph is approved for CE-mark has under EU MDR since 2025. The approval demonstrates the efficacy and safety of pHyph in treating bacterial vaginosis. We want to launch pHyph in partnership with pharmaceutical companies established in women’s health. pHyph …

46 similar entities Type: Startup Activities: biotech deeptech

🫁 Improving the health and lives of patients through effective, safe and convenient inhaled drug delivery PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global …

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Some things cannot be comprised especially quality of life saving drugs, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That`s why, we at Inven, are committed to apply science and our resources, for providing most innovative and quality products. We strive to provide access to safe, effective and affordable medicines to the people who need them. With a strong research oriented work culture, state-of-the-art production facility and end-to-end product development capabilities - Inven is recognized as a leading, ISO 9001-2000 and WHO GMP certified, IV fluid manufacturer in the international and domestic …

136 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Vivani Medical is a pre-clinical-stage developer of long-term pharmaceutical implants aimed at revolutionizing the treatment of patients with chronic diseases. Leveraging its proprietary NanoPortalTM platform, Vivani’s portfolio of tiny, sub-dermal drug implants address medication non-adherence by providing steady levels of medication over a target duration of six months or longer. Vivani is developing two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide). In addition, the company is developing NPM-119, a lower dose exenatide implant for the treatment of type 2 diabetes.

59 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A global medical device company with a goal to reshape the aesthetic experience. Real people, real results. Prollenium Medical Technologies Inc. is a fast-growing Canadian manufacturer and distributor of premium HA dermal filler. We are proud to address all of our client's needs through streamlined medical device innovation. Prollenium is able to ensure a continual flow of creation, unique ideas, and a steady pipeline of new and exciting products that provide safe and effective results. US FDA, Health Canada, and CE approvals, over 4 million syringes in the Revanesse product line have been sold to 80+ countries world-wide. Prollenium is …

78 similar entities Type: SMB Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Next-generation hemoperfusion devices to treat sepsis and multiple organ failure syndrome. Company's flagship product, Efferon LPS single-use hemoperfusion device is granted CE mark approval under EU MDR. Clinically validated approach, over 10.000 treated critical patients. Founded in 2016 to translate the most advanced polymeric adsorbent technology into routine clinical practice and to fight morbid diseases.

Type: Startup Activities: deeptech healthtech

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Zerion Pharma is a pharmaceutical company transforming the landscape for formulation of poorly soluble drugs Zerion is a pharmaceutical company transforming the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas. We are focused on improving existing drug products by building an internal pipeline, while partnering with originators to enable their early stage drug molecules, striving to improve the lives of patients around the world. Pharmaceuticals, Formulation, and Drug delivery

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from …

79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Rapid Therapeutic Drug Monitoring Axithra is a spin-off from Ghent University and imec, developing a platform to quickly and accurately measure and monitor drug concentrations in blood, paving the way for treatments tailored to the specific needs of each individual, at any given time. The first application is focusing on personalizing beta-lactam antibiotics treatments in the intensive care unit. The company’s platform is based on proprietary optical and photonics technology and will allow physicians to optimize patient care by enabling personalized treatments.

160 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing Diagnostics to the Point Of Care Genedrive Diagnostics Ltd is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

What we provide is essential We are a pharmaceutical company dedicated to prioritizing essential medicines and aspiring to improve the health of millions of people around the world. Since our establishment in 2008, our portfolio has grown through the acquisition of 'princeps' medicines from major pharmaceutical companies. We focus on essential medicines recognized by the medical community for their therapeutic value, ensuring their production, marketing, and promotion to healthcare professionals. In doing so, we contribute each year to improving the health of over 2.5 million patients worldwide. Juvisé Pharmaceuticals is now an internationally recognized company, with medicines in neuroscience, gastroenterology, …

224 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our goal to Inspire, Innovate, Impact by Developing Smart Solutions for Animal & Human Reproductive Health. At Pera Labs, we develop digiceuticals and ai-powered solutions for difficult health problems such as fertility. The flagship component of our platform technology for fertility treatments is called SPERMAN, an artificial intelligence based sperm sorter system which provides automated solution for time consuming and labor intensive sperm assessment AND sperm selection procedures. SPERMAN helps fertility clinics perform highly accurate sperm assessment and separation in minutes not days. We take a holistic approach to fertility treatments. Therefore, starting from the assessment of sperm and egg …

78 similar entities Type: Startup Activities: deeptech healthtech Technologies: A.I. A.I. - Deep Learning

Changing The World Naturally At Ultimaxx Health we have made it our mission to develop innovative solutions to pressing public health problems and Natural products that will improve the general health and well being of consumers. Our initial US Patented product is a safe, effective, clinically tested non-narcotic OTC pain relief alternative (tablet form), marketed under the trade name LEVARE® (la-var-ay). LEVARE was developed to help mitigate the epidemic of prescription narcotic "painkiller"​ abuse in the U.S. The U.S. comprises 5% of the world's population and consumes 80% of it's prescription narcotics. Because of this excessive consumption, the U.S. is …

60 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Bio sourced materials

Every Embryo, Every Procedure, Every Cycle Counts Nexpring Health unites industry leaders in reproductive technology, combining over 40 years of expertise from Cook Reproductive Health, Hamilton Thorne Inc., Irvine Scientific, Planer, IVFTech, Gynemed, Gynétics, Microptic, Tek-Event and Embryotech portfolio. We deliver advanced solutions that simplify complex challenges in fertility care, providing unwavering support at every critical moment. Our hands-on partnership goes beyond technology to help clinics deliver consistent, high-quality outcomes for patients worldwide. Assisted Reproductive Technologies, Transgenic Technology, Reproductive Toxicology, Developmental Biology, Animal Breeding/Production, Stem Cell Research, Reproductive Biology, IVF, and In Vitro Fertilization

96 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Collaborating with NIH & DoD to develop treatment options, targeting unmet needs in three multi-billion dollar markets. Virpax is pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours. Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our …

145 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

The natural solution for drug delivery DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend …

86 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Serving patients is a privilege that comes with significant responsibilities. Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2024, we have provided over 180 million units of essential medicines to hospitals, enough to help treat over 80 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more …

107 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

We’re changing the way the world treats inflammation and the way the pharma industry treats humanity Join the revolution! We’re changing the way the world treats inflammation and the way the pharma industry treats humanity. Invest today → https://wefunder.com/senjam Sen-Jam's Global scientists have developed a multi-indication patent and FDA-pending product for the prevention of pain and flu-like symptoms for indications not currently being addressed by the FDA OTC Drug Monograph. It's time for a stronger, more resilient world, free of side-effects and filled with living remarkably Inflammation , Wellbeing, Pain Relief, pharmaceutical, and healthcare

86 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Together, Re-imagining Gynecology with "Gentle" in Mind. Aspivix is a medical device company in women’s health, based in Switzerland and in California, developing next-generation devices for gynecology. Our flagship product, carevix®, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more. Recognized as one the Best Inventions 2024 by TIME, carevix® is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. carevix® study published in …

70 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Advancing the Science of Women's HealthTM Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential …

52 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Improving anaphylaxis management Adan Medical Innovation is a company focused on the improvement of the quality of life of patients that suffer from anaphylaxis, a severe allergic reaction. To achieve this, we have formed a group of experts in different fields (physicians specialized in Allergy and Internal Medicine, business development, patent and regulatory health technologies issues, engineers, information technologies), even including patients among us, and we are working together to offer the best solutions for these patients. The company has developed integrated digital solutions to improve the management of anaphylaxis, having nowadays two different products in its pipeline: AnAPPhylaxis, a …

224 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

We provide healthcare professionals with a superior treatment option, ultimately improving patient outcomes. ArrayPatch Ltd is a clinical stage BioTech company. Our primary mission is to provide healthcare professionals with a superior treatment option, ultimately improving patient outcomes. This mission is centered around our innovative DerMap patent technology, a unique microneedle technology. The first product utilizing DerMap technology will address the fungal infection of the nail. ArrayPatch's robust product pipeline is also expanding into high-value indications including skin cancer, skin aging, migraines, and small peptide therapies for diabetics. Led by an experienced team with a strong international track record in …

63 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Dicot is a pharmaceutical company focused on increasing well-being through innovations that enhance sexual health. Dicot is a pharmaceutical company focused on increasing quality of life and well-being through innovations that enhance sexual health. The company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead candidate, LIB-01, is in clinical stage of development. erectile dysfunction, biopharma, premature ejaculation, drug development, pharma, sexual health, lifestyle , drug discovery, lifestyle, drug discovery, drugs from nature, and biopharmaceutical

100 similar entities Type: Startup Activities: manufacturing deeptech biotech healthtech Technologies: Synthetic Biology

Developing and commercializing products that address unmet needs in women’s sexual and reproductive health. Evofem Biosciences, Inc., (OTCID: EVFM) is a San-Diego based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products. In 2020, we launched PHEXX® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel. In 2024, Evofem acquired and re-launched SOLOSEC® (secnidazole) 2 g oral granules, an FDA-approved single-dose oral antibiotic for the treatment of bacterial vaginosis (BV) and trichomoniasis. Visit phexx.com and solosec.com to learn more and for important safety information.

44 similar entities Type: Startup Activities: biotech deeptech

Developing life-changing, innovative therapies for diseases with unmet needs Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. Intranasal Drug Delivery, Migraine, Parkinson's Disease, CNS Therapeutics, and Autism

238 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

The leader in Prescription Digital Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first …

59 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

We work for a simple, reliable and easy to use diagnostic device to fight the burden of preterm birth. Pregnolia AG is a Swiss medical technology company in the field of preterm birth detection. The company has developed a CE-marked measurement system to accurately determine the stiffness of the cervix. This parameter is an important indicator for assessing the risk of preterm birth. Accurate diagnosis of preterm birth enables immediate interventions to prolong pregnancy and improve the health of newborns. Our vision is that in every gynaecological practice, alongside the ultrasound device, there is a Pregnolia system. medical devices

58 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Unlock the potential of your drug with our expertise in Transdermal and complex Injectable product development Nemaura Pharma is a private specialist biotech company who have developed several advanced versatile skin drug delivery systems. Our technologies have been designed with clinical needs in mind and are all minimally invasive and very cost-effective. We are strategically positioned to work with global pharmaceutical companies, as well as new biotechnology companies, to successfully bring both new and old drugs to patients in superior delivery formulations and systems. Founded in 2005 Nemaura has its headquarters and laboratory facilities in the United Kingdom at the …

172 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Driving Theranostic Innovation for a brighter future ROTOP Pharmaka is a leading pharmaceutical company that manufactures cGMP compliant radiopharmaceuticals for Theranostics in the fields of nuclear medicine and molecular imaging and distributes them in over 45 countries worldwide. The ROTOP brand stands for quality and reliability. We attach great importance to proximity to our customers and optimal services for the best prossible individual solutions. We have over 25 years of experience in developing, manufatcuring, licensing and distributing sterile cold kits for radiolabelled drugs and are continuously expanding the product portfolio together with our strategic partners. Active ingredients, sterile lyophilizates and …

288 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases. This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia …

185 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology